Xu B, Li W, Zhang Q, Li Q, et al. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study. Breast Cancer Res Treat 2022 Dec 4. doi: 10.1007/s10549-022-06775.
PMID: 36463547